Protocols for Primary Cells

Mesenchymal stem cells (MSC), human

Primary Cells	Efficiency	Viable cells	Solution
Adipocytes			
Pre-adipocytes, human, visceral	37-94%	35-90%	P1
Pre-adipocytes, human, subcutaneous	51-84%	33-85%	P1
Pre-adipocytes, human, visceral (Diabetes Type II)	28-65%	64-84%	P1
Pre-adipocytes, human, subcutaneous (Diabetes Type II)	31-70%	61-95%	P1
Bone/Cartilage Cells			
Chondrocyte, human	74%	84%	P3
Dermal Cells			
Keratinocyte, human, neonatal (NHEK)	60-70%	50-60%	P3
Endothelial Cells			
Endothelial, aortic (HAEC), human	73%	70%	P5
Endothelial, microvascular, lung (HMVEC-L), human	79%	48%	P5
Endothelial, umbilical vn.(HUVEC), human	90%	55%	P5
Epithelial Cells			
Epithelial, bronchial (NHBEJ, human	54%	53%	- <u>P3</u>
Epithelial, bronchial, numan, asthmatic	<u>72%</u>	- 75%	- 43
Epithelial, pronchial, numan, CUPD	63% 	- 80%	
Epithelial, mammary (FMEC), numan	51% 	- <u>00%</u> 	P1
	Ur /0	40%	
Fibroblasts			
Fibroblast, dermal (NHDF), human – adult	92-96%	92-100%	P2
Fibroblast, dermal (NHDF), human – neo	98%	86-91%	P2
Fibroblast , embryonic (MEF), mouse	68%	85-90%	P4
Hematopoietic Cells			
B cell mouse stimulated	55-56%	41_87%	P4
B cell, peripheral blood, CD19 ⁺ human	28%	- <u></u> 70%	P3
Dendritic cell. mouse. mature – BALB/c	32%	85%	P3
Dendritic cell, mouse, immat. – BALB/c	43%	37-49%	P4
Dendritic cell, mouse, mature – C57BL/6	29%	88%	P3
Dendritic cell, mouse, immat. – C57BL/6	34%	41-58%	P4
T cell, human stimulated	70%	59%	P3
T cell, human unstimulated	69-87%	53-79%	P3
T cell, mouse – BALB/c	45%	32%	P3
T cell, mouse – C57BL/6	43%	23%	P3
Macrophage, human	42%	60%	P3
Monocyte CD14+, human	64%	77%	P3
Henstocutes			
Henatocute human	54%	59-69%	 P3
	01.0		
Muscle Cells			_
Skeletal Muscle Myoblasts, human	72-78%	61%	P5
SMC, aortic (AoSMC), human	80%	53-80%	P1
Neural Cells			
Neuron, cortical, rat	30-50%		P3
Neuron, hippocampal. rat	30-50%		P3
Stem Cells			
CD34+ cell, bone marrow, human	83%	62%	P3
Embryonic stem (ES) cell, human	64%	98%	P3
Embryonic stem [ES] cell, mouse	86-90%	68-81%	P3

67-71%

Ρ1

69-78%

Protocols for Cell Lines

Cell line	Efficiency	Viable cells	Solution
293	83%	93%	SF
3T3-L1 pre-ad	97%	66-79%	SE
A20	80%		SF
A549	81%	62%	SF
ARPE-19	87%		SE
Ba/F3	80%	60-70%	SG
Beta TC-6	66-77%	49-82%	SF
BHK-21	97–98%	91-95%	SG
C6	92%	55-70%	SF
CHO-K1	86%	97%	SF
CHO-S [suspension]	86%	55-57%	SG
COS-7	91-99%	80-96%	SE
DU 145	89%	86-92%	SE
EL4	70-80%		SE
GH3	60-80%	60-70%	SE
H9C2	80-90%	54-72%	SF
HCT 116	70-80%	65-75%	SE
HeLa	75%	89%	SE
HeLa S3	61-85%	62-95%	SE
Hep G2	95.50%	92.70%	SF
HL-60	58%	61%	SF
HT29	51-67%	60%	SF
IMR32	74-86%	45-63%	SF
IMR90	65%	70%	SE
Jurkat	92%	71-80%	SE
K-562	92%	95%	SF
L-428	70-80%	85%	SF
LnCAP	70%	45%	SF
MCF7	72%	89%	SE
MDA-MB-231	73-89%		SE
MDCK	72-82%	50-55%	SE
MG63	70-73%	60-65%	SE
MRC-5	84-86%	67-73%	SE
Neuro-2a [N2a]	67%	82%	SF
NIH/3T3	95%	93%	SG
РС3	83%	79%	SF
Raji	65-69%	71%	SG
Ramos	40-51%	70-77%	SG
RAW 264.7	60%	86%	SF
RIN-m5F	68-90%	71-85%	SF
Sf9	100%	48-64%	SF
SH-SY5Y	81%	80%	SF
Sp2-0	65-69%	80-90%	SF
T-47D	80%		SE
T84	88%	50-70%	SF
THP-1	65%	81%	SG
U-87MG	75%	40-50%	SE
U-937	36%	85%	SG
Vero	92%	80-95%	SF